Pact Pharma, Inc.
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
none
Next term end
When these terms end
Held patents by the year their term ends
2026 · 0 end2027 · 02028 · 02029 · 02030 · 0
Fee deadlines
No maintenance fee falls due on this company's record before Nov 22, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
No patent on this record is in force and held under this name now.
Also on record: 11 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 5 abandoned
Showing 1 to 10 of 10, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/332,169 | Methods of Treatment Using a Genetically Modified Autologous T Cell Immunotherapy | Jun 9, 2023 | Pending |
| 18/319,743 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY | May 18, 2023 | Pending |
| 18/306,927 | Compositions and Methods for the Treatment of Cancer Using Next Generation Engineered T Cell Therapy | Apr 25, 2023 | Pending |
| 18/049,114 | Methods of Determining Gene Editing Eficiencies in Cells | Oct 24, 2022 | Pending |
| 17/487,411 | Personalized Neoantigen-Specific Adoptive Cell Therapies | Sep 28, 2021 | Pending |
| 17/400,974 | Primary Cell Gene Editing | Aug 12, 2021 | Abandoned |
| 17/099,192 | Methods of Treatment Using a Genetically Modified Autologous T Cell Immunotherapy | Nov 16, 2020 | Abandoned |
| 17/099,140 | Compositions and Methods for the Treatment of Cancer Using a TET2 Engineered T Cell Therapy | Nov 16, 2020 | Abandoned |
| 17/067,101 | Method of Treating Immunotherapy Non-Responders with an Autologous Cell Therapy | Oct 9, 2020 | Abandoned |
| 16/893,166 | Primary Cell Gene Editing | Jun 4, 2020 | Abandoned |